Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular events.

The study, “ Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction–associated steatotic liver disease ,” led by researchers from the Radcliffe Department of Medicine at the University of Oxford, highlights a dangerous feedback loop between the liver and the pancreas. In patients with MASLD, the liver often fails to clear insulin from the bloodstream effectively.

This reduced hepatic insulin clearance leads to chronic hyperinsulinemia, which in turn accelerates the progression of liver fibrosis — the most significant predictor of mortality and severe liver outcomes in metabolic patients. Historically, clinical focus has remained largely on insulin resistance and blood glucose levels.

However, this research argues that the absolute level of fasting insulin provides a unique window into liver health.